Novartis Applies For Approval Of QVA149 For COPD Treatment
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharma announced Nov. 7 it has filed an application for registration of QVA149, a fixed-dose combination of long-acting inhaled bronchodilators indacaterol maleate and glycopyrronium bromide, for the treatment of chronic obstructive pulmonary disease in Japan.